According to filings with the U.S. Securities and Exchange Commission, New Day Diagnostics dba EDP Biotech is raising $15,000,000.00 in new funding. Sources indicate that as part of senior management Director, David Allyn played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About New Day Diagnostics dba EDP Biotech
EDP Biotech Corporation is a privately held medical device company focused on the development and commercialization of blood based immunodiagnostic assays. During this unprecedented pandemic, EDP uses its blood-test technology and partnerships to bring FASTER COVID-19 diagnostic and serology testing as businesses and schools open across the Southeast US. Contact us for more details and to schedule your B2B consultation for testing services. EDPs first commercially focused oncology product, ColoPlex, is a unique multiplex assay to be used in the early detection of colorectal cancer and pre-cancerous polyps.

To learn more about New Day Diagnostics dba EDP Biotech, visit http://www.EDPBiotech.com

Contact:
David Allyn, Director
865-299-6250

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.